Clinical efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide and lamivudine/dolutegravir in the treatment-naive patients with acquired immunodeficiency syndrome  

作　　者：WANG Jiangrong 王江蓉(Dept Infect&Immunol,Shanghai Public Health Clin Center,Fudan Univ,Shanghai 201508,China)

机构地区：[1]Dept Infect&Immunol,Shanghai Public Health Clin Center,Fudan Univ,Shanghai 201508,China

出　　处：《China Medical Abstracts(Internal Medicine)》2024年第3期157-157,共1页中国医学文摘（内科学分册英文版）

摘　　要：Objective To analyze the efficacy and safety of integrase inhibitor-based single-tablet regimens bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and lamivudine/dolutegravir (3TC/DTG) in the treatment-naive patients with acquired immunodeficiency syndrome(AIDS).

关 键 词：PATIENTS immunodeficiency TREATMENT 

分 类 号：R512.91[医药卫生—内科学]